Vericel Corp Files 8-K with Financials/Exhibits
Ticker: VCEL · Form: 8-K · Filed: Aug 26, 2024 · CIK: 887359
Sentiment: neutral
Topics: 8-K, financial-statements, exhibits
TL;DR
Vericel filed an 8-K for routine financial/exhibit updates. No major news.
AI Summary
On August 26, 2024, Vericel Corporation filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating a routine update or disclosure rather than a specific material event. No new financial figures or significant business developments were detailed in the provided excerpt.
Why It Matters
This filing serves as a standard disclosure for Vericel Corporation, providing necessary updates on financial statements and exhibits to the SEC.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for financial statements and exhibits, indicating no immediate material event or change.
Key Players & Entities
- Vericel Corporation (company) — Registrant
- August 26, 2024 (date) — Date of Report
- 64 Sidney Street, Cambridge, MA 02139 (address) — Principal executive offices
- 001-35280 (other) — SEC File Number
- 94-3096597 (other) — I.R.S. Employer Identification No.
FAQ
What is the primary purpose of this 8-K filing for Vericel Corporation?
The primary purpose of this 8-K filing is to report on 'Other Events' and 'Financial Statements and Exhibits' as of August 26, 2024.
What is Vericel Corporation's principal executive office address?
Vericel Corporation's principal executive office is located at 64 Sidney Street, Cambridge, MA 02139.
What is the SEC File Number for Vericel Corporation?
The SEC File Number for Vericel Corporation is 001-35280.
When was Vericel Corporation incorporated?
Vericel Corporation was incorporated in Michigan.
Does this filing indicate any specific new financial results or business developments?
The provided excerpt of the 8-K filing does not detail specific new financial results or business developments; it primarily indicates the filing of financial statements and exhibits.
Filing Stats: 416 words · 2 min read · ~1 pages · Grade level 11 · Accepted 2024-08-26 08:03:45
Filing Documents
- ef20034807_8k.htm (8-K) — 25KB
- ef20034807_ex99-1.htm (EX-99.1) — 30KB
- image00001.jpg (GRAPHIC) — 4KB
- 0001140361-24-038472.txt ( ) — 201KB
- vcel-20240826.xsd (EX-101.SCH) — 4KB
- vcel-20240826_lab.xml (EX-101.LAB) — 21KB
- vcel-20240826_pre.xml (EX-101.PRE) — 16KB
- ef20034807_8k_htm.xml (XML) — 4KB
01
Item 8.01 Other Events On August 26, 2024, Vericel Corporation issued a press release titled "Vericel Announces FDA Approval and Commercial Availability of MACI Arthro." A copy of the press release is attached as Exhibit 99.1 and is incorporated herein by reference.
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits. Exhibit No. Description 99.1 Press Release, dated August 26, 2024, titled "Vericel Announces FDA Approval and Commercial Availability of MACI Arthro." 104 Cover Page Interactive Data File (embedded within the Inline XBRL)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Vericel Corporation Date: August 26, 2024 By: /s/ Sean C. Flynn Name: Sean C. Flynn Title: Chief Legal Officer